HC Wainwright Has Negative Opinion of INBX FY2026 Earnings

Inhibrx Biosciences, Inc. (NASDAQ:INBX – Free Report) – Analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for Inhibrx Biosciences in a note issued to investors on Monday, November 16th. HC Wainwright analyst R. Burns now expects that the company will earn ($9.22) per share for the year, down from their previous estimate of ($8.93). HC Wainwright currently has a “Buy” rating and a $220.00 target price on the stock. The consensus estimate for Inhibrx Biosciences’ current full-year earnings is ($9.91) per share. HC Wainwright also issued estimates for Inhibrx Biosciences’ Q4 2026 earnings at ($2.27) EPS, Q1 2027 earnings at ($2.23) EPS, Q2 2027 earnings at ($2.18) EPS, Q3 2027 earnings at ($1.94) EPS, Q4 2027 earnings at ($1.72) EPS and FY2027 earnings at ($8.02) EPS.

Several other analysts have also issued reports on INBX. Wall Street Zen lowered shares of Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research report on Monday, August 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibrx Biosciences in a report on Friday, September 11th. Finally, Citigroup reaffirmed a “market perform” rating on shares of Inhibrx Biosciences in a research report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $185.00.

Get Our Latest Research Report on Inhibrx Biosciences

Inhibrx Biosciences Trading Down 4.5%

NASDAQ:INBX opened at $74.18 on Wednesday. Inhibrx Biosciences has a one year low of $57.30 and a one year high of $155.29. The company has a fifty day moving average price of $93.60 and a 200 day moving average price of $92.17.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($2.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.45) by ($0.01). The company had revenue of $2.00 million for the quarter, compared to analyst estimates of $1.90 million.

Institutional Trading of Inhibrx Biosciences

Several institutional investors have recently made changes to their positions in INBX. HighTower Advisors LLC increased its stake in Inhibrx Biosciences by 1.6% in the third quarter. HighTower Advisors LLC now owns 884,441 shares of the company’s stock valued at $88,515,000 after acquiring an additional 13,890 shares during the period. Bank of America Corp DE bought a new position in Inhibrx Biosciences during the second quarter worth about $79,698,000. BlackRock Inc. bought a new position in Inhibrx Biosciences during the second quarter worth about $78,261,000. Parkman Healthcare Partners LLC bought a new position in Inhibrx Biosciences during the second quarter worth about $24,346,000. Finally, Soleus Capital Management L.P. acquired a new stake in Inhibrx Biosciences during the third quarter valued at approximately $21,017,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Inhibrx Biosciences news, CEO Mark Lappe purchased 10,040 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were purchased at an average price of $84.56 per share, for a total transaction of $848,982.40. Following the completion of the purchase, the chief executive officer directly owned 745,588 shares of the company’s stock, valued at approximately $63,046,921.28. This represents a 1.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jon Kayyem purchased 5,000 shares of the stock in a transaction on Wednesday, September 23rd. The stock was acquired at an average cost of $100.00 per share, for a total transaction of $500,000.00. Following the acquisition, the director directly owned 434,360 shares in the company, valued at approximately $43,436,000. This trade represents a 1.16% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 62,540 shares of company stock worth $6,347,507 and have sold 1,500 shares worth $168,590. Corporate insiders own 18.26% of the company’s stock.

About Inhibrx Biosciences

(Get Free Report)

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.

Featured Articles

Earnings History and Estimates for Inhibrx Biosciences (NASDAQ:INBX)

Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.